Strategic Partnerships With Palforzia as an FDA approved peanut allergy therapy and the CODIT platform, Aimmune offers opportunities for co development, licensing, and co commercialization with healthcare providers, payers, and regional distributors to scale current therapies and extend the pipeline in US and international markets.

Global Market Access Nestlé Health Science backing and a multi region footprint (US, UK, Ireland, Germany) position Aimmune for rapid regulatory navigation, manufacturing collaboration, and multi market distribution, enabling business development teams to pursue cross border deals and payer engagement strategies.

Pipeline Expansion Aimmune's investigational portfolio beyond Palforzia and the CODIT approach provides avenues for strategic alliances to accelerate development timelines, share risk and cost, and monetize new allergen therapies through milestone driven deals alongside Nestlé's R&D and manufacturing capabilities.

Commercial Readiness Current revenue level and solid funding, combined with Nestlé support, suggest readiness for scaled commercial efforts; business development opportunities include co promotion, patient access programs, and payer negotiation partnerships to maximize uptake in existing and new markets.

Leadership Signals Recent leadership changes and board level additions indicate strategic realignment and potential openness to new partnerships; engage early with new leadership to align on priority indications, go to market plans, and potential joint ventures.